CANbridge Pharmaceuticals Inc. (1228.HK)
HKD 0.15
(-1.35%)
HKD 0.15
(-1.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.02 Million CNY | 105.76% |
| 2022 | -295.87 Million CNY | 57.35% |
| 2021 | -693.71 Million CNY | -120.99% |
| 2020 | -313.9 Million CNY | -656.56% |
| 2019 | 56.4 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.29 Million CNY | -119.33% |
| 2024 Q2 | -3.29 Million CNY | 3272.26% |
| 2023 Q2 | -119.34 Million CNY | 15.69% |
| 2023 FY | 17.02 Million CNY | 105.76% |
| 2023 Q4 | 17.02 Million CNY | 358.16% |
| 2023 Q3 | -6.59 Million CNY | 94.47% |
| 2023 Q1 | -141.55 Million CNY | 52.16% |
| 2022 Q1 | -453.71 Million CNY | 34.6% |
| 2022 Q4 | -295.87 Million CNY | 7.78% |
| 2022 FY | -295.87 Million CNY | 57.35% |
| 2022 Q3 | -320.85 Million CNY | 28.4% |
| 2022 Q2 | -448.15 Million CNY | 1.23% |
| 2021 Q4 | -693.71 Million CNY | 1.12% |
| 2021 Q1 | 1.82 Billion CNY | 682.09% |
| 2021 Q2 | -412.15 Million CNY | -122.56% |
| 2021 FY | -693.71 Million CNY | -120.99% |
| 2021 Q3 | -701.59 Million CNY | -70.23% |
| 2020 Q4 | -313.9 Million CNY | -116.99% |
| 2020 Q3 | 1.84 Billion CNY | 0.0% |
| 2020 FY | -313.9 Million CNY | -656.56% |
| 2019 FY | 56.4 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 122.297% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 99.677% |